{"organizations": [], "uuid": "11bebe435e1d487fee8eeca40cd0fccef22ef0e1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180427.html", "section_title": "Archive News &amp; Video for Friday, 27 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-celyads-cyad-01-induced-complete-r/brief-celyads-cyad-01-induced-complete-remission-in-relapsed-refractory-aml-patient-idUSFWN1S40JN", "country": "US", "domain_rank": 408, "title": "BRIEF-Celyad's CYAD-01 Induced Complete Remission In Relapsed/Refractory AML Patient", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.192, "site_type": "news", "published": "2018-04-27T14:33:00.000+03:00", "replies_count": 0, "uuid": "11bebe435e1d487fee8eeca40cd0fccef22ef0e1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-celyads-cyad-01-induced-complete-r/brief-celyads-cyad-01-induced-complete-remission-in-relapsed-refractory-aml-patient-idUSFWN1S40JN", "ord_in_thread": 0, "title": "BRIEF-Celyad's CYAD-01 Induced Complete Remission In Relapsed/Refractory AML Patient", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "aml", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 27 (Reuters) - CELYAD SA:\n* HAEMATOLOGICA PUBLISHES CELYAD THINK STUDY CASE REPORT OF CYAD-01 INDUCED COMPLETE REMISSION IN RELAPSED/REFRACTORY AML PATIENT\n* PATIENT ACHIEVED A COMPLETE MOLECULAR REMISSION AND REMAINS IN REMISSION 9 MONTHS POST STUDY ENROLLMENT\n* CYAD-01 WAS WELL TOLERATED WITH NO SIGNIFICANT TOXICITIES\n* DEMONSTRATED 1ST OBJECTIVE RESPONSE TO ANY CAR-T IN RELAPSED/REFRACTORY AML WITHOUT PRECONDITIONING CHEMOTHERAPY HIGHLIGHTS POTENTIAL OF CYAD-01 AS TREATMENT FOR AML Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-27T14:33:00.000+03:00", "crawled": "2018-04-28T12:25:39.048+03:00", "highlightTitle": ""}